TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19699443

Group type: EXPERIMENTAL
Intervention: Higher densities of employees in neighborhood destinations for youth
Number of subjects: 152

Group type: COMPARATOR
Intervention: Lower densities of employees in neighborhood destinations for youth
Number of subjects: 152
Study: 18991158

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waiting list Control Group (n=7)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined groups at 3-month follow-up
Number of subjects: 14
Study: 15804684

Group type: EXPERIMENTAL
Intervention: Active 21‐mg nicotine patch
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Active 2‐mg or 4-mg nicotine lozenge
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Placebo (for both patch and lozenge)
Number of subjects: 1309
Study: 12153829

Group type: EXPERIMENTAL
Intervention: WS 5570 (300 mg t.i.d.)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 10340155

Group type: EXPERIMENTAL
Intervention: Pleasant odor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpleasant odor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control odor (water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odors eliciting negative-affect-related expressions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odors that did not elicit negative-affect-related expressions
Number of subjects: 0
Study: 7562226

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulator (TENS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study: 2085991

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT) 3 g single dose
Number of subjects: 291

Group type: COMPARATOR
Intervention: Pipemidic acid (PA) 400 mg b.i.d. for seven days
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FT)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Pipemidic acid (PA)
Number of subjects: 291
Study: 343660

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg t.i.d.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isoproterenol (0.15 mg t.i.d.)
Number of subjects: 28
Study: 29807811

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated nasal packing
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Steroid-impregnated nasal packing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline solution-impregnated nasal packing
Number of subjects: 80
Study: 28333952

Group type: EXPERIMENTAL
Intervention: OM-85 (3.5mg daily for 9 months)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 24444038

Group type: COMPARATOR
Intervention: T1DM-P (HbA1c ≥ 9.0%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: T1DM-G (HbA1c ≤ 7.5%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (T1DM-G, T1DM-P, controls)
Number of subjects: 24
Study: 23932793

Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pill-placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study: 21808844

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1 mg/kg midazolam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (0.1 ml/kg orange flavored juice)
Number of subjects: 90
Study: 19095163

Group type: EXPERIMENTAL
Intervention: FC-Interactive Voice Response (IVR) counseling
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: FC-Interactive Voice Response (IVR) counseling (with at least six completed calls)
Number of subjects: 220

Group type: COMPARATOR
Intervention: FC-workbook
Number of subjects: 220

Group type: COMPARATOR
Intervention: FC-group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 220
Study: 16525095

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 587

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 587
Study: 12406891

Group type: EXPERIMENTAL
Intervention: CD34+‐selected PBSCs
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unselected PBSCs
Number of subjects: 32
Study: 10759039

Group type: EXPERIMENTAL
Intervention: Single-session (SS) treatment
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Treatment-as-needed (TAN)
Number of subjects: 105
Study: 8832303

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid with glycine (test formulation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid without glycine (reference formulation)
Number of subjects: 12
Study: 1486964

Group type: EXPERIMENTAL
Intervention: Amiloride (10(‐2) M)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6428120

Group type: EXPERIMENTAL
Intervention: Insulin + glibenclamide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Insulin + placebo
Number of subjects: 13
Study: 30902539

Group type: EXPERIMENTAL
Intervention: Reaching backward
Number of subjects: 41

Group type: COMPARATOR
Intervention: Reaching forward
Number of subjects: 41
Study: 30029290

Group type: EXPERIMENTAL
Intervention: Near-infrared indocyanine green (ICG) fluorescence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual assessment under white light
Number of subjects: 0
Study: 27234693

Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1369
Study: 24491201

Group type: EXPERIMENTAL
Intervention: Brief, exposure-based intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 40
Study: 21833487

Group type: EXPERIMENTAL
Intervention: Footbath (30 min immersion in water at 41 to 43°C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no footbath)
Number of subjects: 32
Study: 20920045

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS) injected once or twice daily
Number of subjects: 471

Group type: COMPARATOR
Intervention: Insulin glargine injected once daily
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Insulin lispro protamine suspension (ILPS)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 471
Study: 18389675

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Essential oil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Azadirachta indica (Neem) extract
Number of subjects: 80
Study: 15804248

Group type: EXPERIMENTAL
Intervention: Oral creatine (Cr) monohydrate at a dosage of 150 mg/kg body weight/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12519334

Group type: EXPERIMENTAL
Intervention: Early loading of ITI implants (6 weeks healing)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional loading of ITI implants (12 weeks healing)
Number of subjects: 24
Study: 10233426

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 8598501

Group type: EXPERIMENTAL
Intervention: Functional posted foot orthoses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo orthoses
Number of subjects: 0
Study: 1844168

Group type: EXPERIMENTAL
Intervention: Modified cow's milk formula (LPM)
Number of subjects: 2097
Study: 7201816

Group type: EXPERIMENTAL
Intervention: Fluocortolone monohydrate (Syracort) applied at 4-13-day intervals
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Syracerin (steroid-free partner drug) applied at 4-13-day intervals
Number of subjects: 1573

Group type: EXPERIMENTAL
Intervention: Interval application of topical corticoids
Number of subjects: 1573
Study: 30829316

Group type: EXPERIMENTAL
Intervention: ZEB1 siRNA
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Scramble group
Number of subjects: 2
Study: 30548426

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO; 145 g; n=9)
Number of subjects: 17
Study: 26719947

Group type: EXPERIMENTAL
Intervention: Immediate prescription strategy
Number of subjects: 405

Group type: COMPARATOR
Intervention: No prescription strategy
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Delayed prescription collection strategy
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Delayed patient-led prescription strategy
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: All delayed strategies (patient-led and collection)
Number of subjects: 405
Study: 24557661

Group type: EXPERIMENTAL
Intervention: escitalopram (ESC) + bupropion (BUP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: escitalopram (ESC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: bupropion (BUP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: BUP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Baseline alpha2 power
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Alpha2 asymmetry
Number of subjects: 51
Study: 21813573

Group type: EXPERIMENTAL
Intervention: 25‐min lower‐limb resistance exercises with vascular measurements in the calf (RELL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 25‐min lower‐limb resistance exercises with vascular measurements in the forearm (REUL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 25‐min rest (control)
Number of subjects: 10
Study: 20670733

Group type: EXPERIMENTAL
Intervention: Selenium 200 microg/day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Selenium 800 microg/day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 17513173

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg/day until disease progression
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard gemcitabine infusion
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PCI gemcitabine 1200 mg/m(2) in a 120-min infusion
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 400
Study: 17027423

Group type: EXPERIMENTAL
Intervention: Herbal interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 12175131

Group type: EXPERIMENTAL
Intervention: Prophylaxis (specific details not provided)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control groups (Group A, Group B, Group C)
Number of subjects: 30
Study: 10452209

Group type: EXPERIMENTAL
Intervention: Three telephone calls and oral and written self-care measures for specific side effects
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Higher ESCA scores before chemotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Telephone call and written self-care measures after the second, third, and fourth chemotherapy treatments
Number of subjects: 48
Study: 7598066

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (20 mmol/24 h)
Number of subjects: 68
Study: 2180341

Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin (0.14 mg/kg)
Number of subjects: 0
Study: 288173

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31634532

Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 30994790

Group type: EXPERIMENTAL
Intervention: Cryotherapy accompanied by 1% gentian violet application (group 2)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cryotherapy alone (group 1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study: 29085387

Group type: EXPERIMENTAL
Intervention: TCMS plus PEDT combination therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: TCMS monotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: PEDT monotherapy
Number of subjects: 90
Study: 25327838

Group type: EXPERIMENTAL
Intervention: Suicide Attempt (SA)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Suicidal Ideation (SI)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Comparison between SA and SI groups
Number of subjects: 181

Group type: COMPARATOR
Intervention: Parent and youth self-reports
Number of subjects: 181

Group type: COMPARATOR
Intervention: Independent judges and youth reports
Number of subjects: 181
Study: 23372095

Group type: COMPARATOR
Intervention: Oncology nurse navigator program
Number of subjects: 0
Study: 21792758

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with combined preoperative intraarterial infusion and intravenous chemotherapy before gastrectomy and D2 lymphadenectomy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Gastrectomy and D2 lymphadenectomy alone
Number of subjects: 139
Study: 19472556

Group type: EXPERIMENTAL
Intervention: Test Paste (8% arginine and calcium carbonate)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control Paste (Nupro pumice prophylaxis paste)
Number of subjects: 68
Study: 17257877

Group type: EXPERIMENTAL
Intervention: Nasal vaccine candidate (50 microg HBsAg and 50 microg HBcAg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (0.9% physiologic saline solution)
Number of subjects: 19
Study: 14665895

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg once daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Saw palmetto (325 mg daily)
Number of subjects: 64
Study: 11695935

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg, twice daily for 12 months)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (200 microg, twice daily for 12 months)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 277

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and Beclomethasone dipropionate
Number of subjects: 277
Study: 10799790

Group type: EXPERIMENTAL
Intervention: Cognitively intact patients
Number of subjects: 97

Group type: COMPARATOR
Intervention: Patients with advanced dementia
Number of subjects: 97
Study: 8615323

Group type: EXPERIMENTAL
Intervention: ACEI (5 mg ramipril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1729872

Group type: EXPERIMENTAL
Intervention: Standard Bruce protocol
Number of subjects: 32
Study: 6373158

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen twice daily
Number of subjects: 226

Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 226
Study: 30768429

Group type: EXPERIMENTAL
Intervention: Use of electronic health record‐based clinical decision support (CDS) tools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30475912

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 4011

Group type: COMPARATOR
Intervention: No GTN
Number of subjects: 4011

Group type: EXPERIMENTAL
Intervention: Investigator reported events
Number of subjects: 4011
Study: 26215167

Group type: EXPERIMENTAL
Intervention: Fit Body and Soul (FBAS)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 604
Study: 24112747

Group type: EXPERIMENTAL
Intervention: Mediolateral episiotomy (MLE)
Number of subjects: 790

Group type: COMPARATOR
Intervention: Lateral episiotomy (LE)
Number of subjects: 790
Study: 22397833

Group type: EXPERIMENTAL
Intervention: 2-year multi-component intervention in low-SES community
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Low-SES control community
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Total sample (both intervention and control)
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Intervention effects on eating behaviour, physical activity, or screen-time
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Interaction effects of age and gender
Number of subjects: 1102
Study: 21154265

Group type: EXPERIMENTAL
Intervention: L-arginine (8 g/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Citrulline malate (3 g/day)
Number of subjects: 30
Study: 16969378

Group type: EXPERIMENTAL
Intervention: DHA diet
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: EPA diet
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ALA diet
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: ALA group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: EPA group
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: DHA group
Number of subjects: 61
Study: 16253720

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3603
Study: 12121721

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9469327

Group type: EXPERIMENTAL
Intervention: Lumpectomy plus radiation (50 Gy)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 818
Study: 7883113

Group type: EXPERIMENTAL
Intervention: Regular beef/pork insulin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 13
Study: 2168836

Group type: EXPERIMENTAL
Intervention: Moderately noxious temperature (46 degrees C) applied to the contralateral hand for 2 minutes
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (0.4 mg i.v.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 31488484

Group type: EXPERIMENTAL
Intervention: Up to five video consultations conducted by a mental health specialist
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual as provided by their general practitioner
Number of subjects: 50
Study: 28417203

Group type: EXPERIMENTAL
Intervention: Tailored mailed print diet and exercise interventions
Number of subjects: 50
Study: 25226336

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Standing Climb (SC)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Seated
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Medium-high RPE
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High RPE
Number of subjects: 11
Study: 23627714

Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure for 30 minutes, 10 weekly visits; 192 millitesla peak‐to‐peak value
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non‐magnetized pads (sham) for 30 minutes, 10 weekly visits
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure
Number of subjects: 11
Study: 21823377

Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine (15 ml of 0.5%)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no epidural levobupivacaine)
Number of subjects: 90
Study: 20368213

Group type: EXPERIMENTAL
Intervention: muraglitazar (0.5, 1.5, 5, 10, and 20 mg)
Number of subjects: 1477

Group type: COMPARATOR
Intervention: pioglitazone (15 mg)
Number of subjects: 1477

Group type: EXPERIMENTAL
Intervention: muraglitazar
Number of subjects: 1477

Group type: COMPARATOR
Intervention: pioglitazone
Number of subjects: 1477
Study: 17111783

Group type: EXPERIMENTAL
Intervention: Ribavirin plus IFN alpha‐2b 5 MU/day for 1 month followed by IFN alpha‐2b 5 MU thrice weekly for 5 months (Group A)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Ribavirin plus IFN alpha‐2b 5 MU thrice weekly for 6 months (Group B)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Induction therapy (Group A)
Number of subjects: 175
Study: 15576968

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-generation dihydropyridinoline CCBs
Number of subjects: 0
Study: 11727875

Group type: EXPERIMENTAL
Intervention: Dioptric training (powered flipper training)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham treatment (plano lens training)
Number of subjects: 13
Study: 8981375

Group type: EXPERIMENTAL
Intervention: New stimuli presented in hierarchical perception task
Number of subjects: 2

Group type: COMPARATOR
Intervention: Previous study with unilateral or bilateral presentation
Number of subjects: 2
Study: 7956629

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) insulin infusion via programmable implantable pumps
Number of subjects: 10

Group type: COMPARATOR
Intervention: Multiple subcutaneous (SC) injections
Number of subjects: 10
Study: 3555691

Group type: EXPERIMENTAL
Intervention: Reversed grafts
Number of subjects: 215

Group type: COMPARATOR
Intervention: In situ grafts
Number of subjects: 215

Group type: COMPARATOR
Intervention: Reversed grafts and In situ grafts
Number of subjects: 215
Study: 31113167

Group type: COMPARATOR
Intervention: Karydakis flap (KF group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Limberg flap (LF group)
Number of subjects: 80
Study: 28330458

Group type: EXPERIMENTAL
Intervention: Standardised 1-year extensive aerobic exercise intervention (3 units of 45 min/week)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Stretching and toning (non-aerobic) exercise (3 units of 45 min/week)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study: 25363423

Group type: COMPARATOR
Intervention: Continuous use of occlusal splints (29 nights continuously)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intermittent use of occlusal splints (used on the 1st‐7th, 15th‐21st, and 29th nights)
Number of subjects: 20
Study: 23103453

Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Speed training
Number of subjects: 1659
Study: 21234629

Group type: EXPERIMENTAL
Intervention: Multidisciplinary treatment combining cognitive behavioural therapy (CBT), graded exercise therapy (GET), and pharmacological treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual treatment (exercise counselling and pharmacological treatment)
Number of subjects: 120
Study: 19450101

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg weekly
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 1000